A

Alexion

Global biopharmaceuticals focusing on rare diseases

Field Reimbursement Manager - Rare Neurology, Hematology, & Nephrology

Full-TimePosted on 10/21/2026Deadline 11/2/26
$147k - $220.5k/yr+ Short-term incentive bonuses + Equity-based awards
Mid, Senior
Bachelor's
United States
In Person
Customer Experience & SupportCustomer Success

About the job

Requirements
  • A bachelor's degree is required.
  • Five to seven years of experience in the healthcare and/or pharmaceutical or biotechnology industry is required.
  • At least three years of experience working with buy-and-bill and/or specialty pharmacy networks is required.
  • At least three years of field reimbursement experience is required.
  • Understanding of access processes, including medical and pharmacy benefit design and the transition from prescription to infusion or injection, is required.
  • Experience with products requiring prior authorization and a clear understanding of related billing, coding, and in-office support are required.
  • The ability to communicate effectively with people at all levels, inside and outside the company, is required.
  • The ability to educate physicians and other healthcare professionals confidently and expertly in an office procedural environment is required.
  • Experience working through complex reimbursement issues is required.
  • Experience working with billing and medical claim personnel in a healthcare setting is required.
  • Experience working with integrated health systems is required.
  • Technical aptitude and working proficiency with an iPad, laptop, customer relationship management systems, Microsoft Word, Excel, PowerPoint, and Outlook are required.
  • Willingness to travel with equipment to coordinate daily with key partners on education and case work is required.
  • The role requires travel to work-related meetings and functions, including overnight travel of up to four nights per week, and travel of 60–75%.
  • The role requires the ability to drive to assigned targets within the territory using a company-provided fleet electric vehicle.
  • A valid driver's license and clean driving record are required.
  • The role requires the ability to travel regionally and cover large, multi-state territories.
  • The employee must reside in the assigned territory; relocation assistance is not provided.
  • The employee must be able, with or without accommodation, to travel by public transportation, automobile, train, or plane; work comfortably in a clinical setting; use a computer; communicate via phone, video, and electronic messaging; problem-solve; engage in complex and non-linear thought, analysis, and dialogue; collaborate with others; maintain general availability during standard business hours; and complete operational reporting while traveling.
  • The employee must comply with laws, regulations, company policies, and the company's Code of Ethics and Business Conduct.
Responsibilities
  • Partner with cross-functional teams on account and territory planning and strategy to improve internal and external customer knowledge of payer policies and processes, and routinely document and present plans.
  • Serve as a subject matter expert on reimbursement and the regional access landscape, including medical and pharmacy benefit design, product acquisition, payer policies and coverage criteria, prior authorization requirements, denials, appeals, peer-to-peer education, and other education needed to navigate coverage for assigned indications and therapies, in compliance with company policy, legal requirements, and standards.
  • Develop and execute strategic account and territory plans that increase customer knowledge of reimbursement and access processes, using available resources, internal data, and field insights to prioritize activity and guide call objectives.
  • Collaborate with patient services on individual case-management needs related to healthcare provider education on reimbursement issues.
  • Identify, document, and communicate field insights about payer policy shifts, access barriers, denial trends, operational challenges, and customer education needs to inform internal planning and decisions.
  • Share insights and coordinate activities with cross-functional partners; attend internal meetings with relevant market access, patient services, medical, sales, compliance, legal, and other partners, as well as company meetings as requested.
  • Maintain accurate documentation and operational reporting on customer interactions, account plans, healthcare provider office education, and case-related activity in customer relationship management and other approved systems.
  • Manage work in alignment with annual priorities, key performance indicators, territory objectives, project priorities, and approved budget parameters.
Desired Qualifications
  • Rare disease experience is preferred.
  • Understanding of top regional and national payers within the assigned geography is preferred.
  • Experience launching a new specialty pharmaceutical or biologic product, or a new product indication, is preferred.
  • Neurology, hematology, and/or nephrology experience is preferred.
  • Experience working through complex reimbursement issues is preferred.
  • Experience working with billing and medical claim personnel in a healthcare setting is preferred.
  • Prior Authorization Certification Specialist (PACS) certification is preferred.
  • Familiarity with applying artificial intelligence tools and techniques to enhance efficiency is preferred.
  • Residence within Wisconsin or Northern Illinois is preferred.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old